Participation in any investigational drug study (excluding non-oncology and/or symptom management studies) within  weeks prior to registration.
Prior participation in an investigational study (drug, procedure or device) within  days of study day .
Participation in an interventional, investigational study within  weeks of the first dose of study treatment.
Prior participation in a clinical study of viagenpumatucel-L
Participation in other studies involving investigational drug(s) within  weeks prior to study entry and/or during study participation.
Previous participation in a clinical study of IV or oral rigosertib; patients who failed screening for other rigosertib studies may be screened for participation
Prior participation in an investigational study within  days of study day 
Participation in any investigational drug study within  weeks preceding enrollment
Participation in other studies involving investigational drug(s) within  weeks prior to study entry and/or during study participation
Current enrollment in an investigational drug or device study or participation in such a study within  days of cycle  day .
Prior participation in this study
Participation in another investigational drug study in the prior  weeks
Participation in a prior investigational study within  weeks prior to enrollment or longer if required by local regulation
Participation in an investigational drug or device study or treatment with any antineoplastic agent within  days of the first day of dosing on this study
Participation in an investigational drug or device study within  days of the first day of dosing on this study
Participation in an investigational new drug trial within  days prior to initiating treatment on study
Subjects with leukemia are not eligible for study participation
Participation in an investigational drug study or history of receiving any investigational treatment within  days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
Discontinued study participation in Verastem-sponsored IPI-- study
Participation in other studies involving investigational drug(s) within  days prior to study entry and/or during study participation;
Part : able to understand the recommendations for participation in the study
Participation in any investigational drug study within  weeks preceding the start of study treatment
Participation in a prior investigational study within  days prior to enrollment
Current or recent treatment with another investigational drug within  days of first study treatment dosing or earlier participation in this study
Current or recent (within  days of first study dosing) treatment with another investigational drug or participation in another investigational study
Concurrent participation in any other investigational study
Participation in any investigational drug study within  weeks preceding the start of study treatment; patients are not permitted to participate in another investigational drug study while being treated on this protocol
Participation in another research study involving an investigational agent within  days prior to consent or projected study participation during the  days post study randomization.
Participation in a therapeutic research study or receipt of an investigational drug within  weeks of leukapheresis
Participation in an interventional, investigational study within  weeks of the first dose of study treatment.
Participation in another investigational drug study in the prior  weeks
Participation in an investigational anti-cancer study within  weeks prior to day - (beginning of loading phase)
Participation in any investigational drug study within  weeks preceding the start of study treatment
Current enrollment in an investigational drug or device study or participation in such a study within  weeks of cycle , day 
Participation in any other investigational drug study within  weeks of study enrollment
Participation in other studies involving investigational drug(s) within  weeks prior to study participation and/or during study participation.
Current enrollment in an investigational drug or device study or participation in such a study within  days of enrollment
Previous participation in a stem cell study within last  days
Participation in an investigational therapeutic study within  weeks prior to first dose
Participation in any investigational drug study within  weeks preceding the start of study treatment
Participation in any investigational drug study within  weeks preceding the start of study treatment
Participation in any investigational drug study within  weeks preceding the start of study treatment
Current participation in other clinical study
Participation in any clinical study or having taken any investigational therapy within  days.
current participation in other clinical study
Participation in other studies involving investigational drug(s) (Phases -) within  weeks of registering for the current study and/or during study participation.
Participation in other studies involving investigational drug(s) (Phases -) before the current study begins and/or during study participation.
Simultaneous participation in any other study involving investigational drugs or having participated in a study less than  weeks prior to treatment in this study
Female patients may not be breastfeeding at screening and must not breastfeed during study participation through  days after the last dose of study drug.
Participation in other study using an investigational or experimental therapy or procedure within  weeks or  half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study
Participation in any investigational drug study within  weeks preceding the start of study treatment
Prior participation in an investigational study (procedure or device) within  days of study day 
Previous participation in a clinical study of Kevetrin
Have previously received an investigational BET inhibitor (including previous participation in this study or Study ZEN-)
Participation in another clinical study with an investigational drug within  days of Screening.
Participated in any previous study of aprepitant or fosaprepitant, or taken an investigational drug within  weeks prior to study participation
Current participation in a treatment study or past participation in a study of an investigational agent within  weeks before the first dose of study treatment
Current participation in a treatment study or past participation in a study of an investigational agent within  weeks before the first dose of study treatment
Females must agree to abstain from breastfeeding during study participation and  days after study drug discontinuation
Participation in an investigational therapeutic study within  days of initiation of study drug treatment
Likely to continue to need treatment of OIC for the duration of participation in the study.
Participation in a study with an investigational drug from  weeks prior to study start until study end
Participation in any other clinical study within the last  weeks prior to the start of the study
Female patients must not be breastfeeding at screening nor during the study participation until  days after the last dose of the study drug.
Female patients must not be breastfeeding at screening nor during the study participation until  days after the last dose of study drug.
Concomitant participation in any other investigational treatment study; simultaneous participation in non-therapeutic or observational studies will not be an exclusion criterion
Declined participation in the study
Approval of Oncology provider for participation in this study
Participation in any investigational drug study within  weeks preceding the start of study treatment
Have previously received an investigational BET inhibitor (including previous participation in this study or Study ZEN-)
Participation in an interventional, investigational non-immunotherapy study within  weeks of the first dose of study treatment.
Participation in any other investigational treatment within the  weeks prior to enrollment or concurrent with this study.
Participation in another clinical study within  days of the day chemotherapy is initiated, in which the study drug or device may influence hematopoiesis. Co-enrollment in another study is allowed in cases where the investigational therapy under study is a version of an acceptable chemotherapy regimen for this study per the inclusion criteria.
Previous participation in this study
Participation in any study with an investigational compound or device within  days prior to signing informed consent
Participation in other study using an investigational or experimental therapy or procedure within  weeks or  half-lives (whichever is longer) before the screening visit and/or during study participation; subjects cannot participate in studies of other investigational or experimental therapies or procedures at any time during their participation in this study
Participation in other research protocols does not exclude a patient from participation in this study
Participation in any other study in last  days
Participation in another clinical study in the month preceding this study
Participation in other clinical study within the last  days
Participation in a therapeutic clinical study within  weeks before study drug treatment (for small-molecule targeted agents, this non-participation period is  weeks or  half-lives, whichever is longer), or current participation in other investigational procedures.
Participation in more than  research studies in the past  months. Participation in a smoking study in the past  months. Participation in a study which involved medication within the last month